Clomipramine (25 mg) taken as needed increases ejaculatory latency in men with rapid ejaculation (RE), although only about half the men treated respond to this regimen. It would therefore be clinically advantageous to know the patient's potential responsiveness to an 'as needed' regimen prior to treatment. The present study attempted to identify a priori factors that might enable prediction of patients' response or nonresponse to 'as needed' clomipramine. Variables relevant to rapid ejaculation were examined in 23 men with RE, 12 of whom had responded to clomipramine. Logistic regression indicated that three factors assessed prior to treatment-initial ejaculation latency, overall sexual satisfaction, and ejaculation frequency each week-significantly improved the prediction of responsiveness to this treatment regimen. Specifically, RE men with initial ejaculatory latencies over 60s, self-reported sexual satisfaction of 5 or higher (on a seven-point scale), and ejaculation frequency of twice or more weeldy were more likely to benefit from 25 mg 'as needed' clomipramine. As such, men meeting these criteria might be considered for this treatment regimen. Those not matching these characteristics might better be considered for 20 or 30 mg clomipramine given on a daily basis.

, , , , ,,
International Journal of Impotence Research
Department of Reproduction and Development

Rowland, D, Tai, W.L, Brummett, K, & Slob, A.K. (2004). Predicting responsiveness to the treatment of rapid ejaculation with 25 mg clomipramine as needed. International Journal of Impotence Research, 16(4), 354–357. doi:10.1038/sj.ijir.3901161